US exempts specialty drugs from tariffs, benefiting Indian pharma firms

The United States Commerce Department has granted tariff relief on specialty pharmaceutical products imported from India and a total of 20 countries worldwide, marking a significant development for Indian drugmakers.

The exemption applies to ad valorem tariffs on select medications and their raw material ingredients used across multiple therapeutic categories. Products eligible for the tariff waiver include those employed in treating rare diseases, fertility and reproductive medicine, cell and gene therapies, antibody-drug conjugates, and veterinary pharmaceuticals.

The decision is expected to ease cost pressures on Indian pharmaceutical manufacturers who supply these specialized drug categories to the US market. India's pharmaceutical industry, which has established itself as a major global supplier of generic and specialty medicines, stands to benefit from reduced tariff burdens on high-value pharmaceutical components.

The move reflects Washington's recognition of the importance of uninterrupted supply chains for critical and specialized pharmaceutical products. Industry analysts view the exemption as a positive signal for Indian pharma companies' competitiveness in the US market, particularly in niche therapeutic segments where India has developed significant manufacturing capabilities.

The Commerce Department's decision underscores the ongoing balance between trade policy objectives and the practical needs of pharmaceutical supply chains serving both domestic and international patients.